Joel Lewis - 05 Jan 2026 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Reporting relationship: President and CEO, Director
Issuer ticker: GALT
Reported as of: 05 Jan 2026
Net transaction value: -$218,568
SEC form: 4
Accepted by SEC: 13 Jan 2026, 08:40:08 UTC
Prior SEC filing: 06 Jan 2026
Next SEC filing: 22 Jan 2026
Source filing: View source filing
Reporting owner signature: Jack W. Callicutt, by power of attorney

Key filing fact

Joel Lewis filed Form 4 for GALECTIN THERAPEUTICS INC (GALT) on 13 Jan 2026.

Key facts

This page summarizes Joel Lewis's Form 4 filing for GALECTIN THERAPEUTICS INC (GALT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Jan 2026, 08:40.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: -$218,568.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001725595 Primary reporting owner

LEWIS JOEL

Relationship: President and CEO, Director
Address: C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS
Signature: Jack W. Callicutt, by power of attorney
Signature date: 13 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GALT transaction

Common Stock

No transaction description listed

Transaction value: $218,568
Shares: -56,332
Change %: -6.8%
Price: $3.88
Shares after: 776,260
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F1, F2, F3

GALT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,000
Date: 05 Jan 2026
Ownership: as USTA custodian for a minor child
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units ("DSUs") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs from the amended agreement shall be settled in shares of Common Stock as follows: (i) fifty percent shall be settled on March 1, 2025 and (ii) fifty percent shall be settled on January 5, 2026.

Footnote F2

Represents shares underlying DSUs and Common Stock.

Footnote F3

Represents shares withheld from issuance to Mr. Lewis (but not sold) for federal and state withholding taxes on income.

Footnote F4

These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.